deni
insur
patient
initi
screen
lack
avail
haploident
donor
elev
donorspecif
antibodi
dsa
declin
proceed
hsct
patient
transplant
receiv
peripher
blood
stem
cell
initi
condit
alemtuzumabtot
bodi
irradi
tbi
gy
follow
posttranspl
cyclophosphamid
fail
engraft
next
patient
receiv
regimen
develop
john
hopkin
univers
tbi
gy
granulocyt
colonystimul
factor
administ
day
hb
patient
engraft
median
time
neutrophil
l
day
rang
one
patient
subsequ
lost
graft
maintain
donor
cell
chimer
posthsct
two
patient
develop
acut
graftversushost
diseas
gvhd
least
grade
ii
one
chronic
gvhd
die
year
hsct
unknown
caus
median
followup
month
rang
patient
aliv
find
suggest
limit
insur
coverag
high
rate
dsa
patient
declin
hsct
may
limit
avail
haploident
hsct
adult
scd
patient
modifi
hopkin
regimen
use
demonstr
high
engraft
low
morbid
rate
test
larger
multicent
prospect
clinic
trial
allogen
nonmyeloabl
hematopoiet
stem
cell
transplant
hsct
hlamatch
relat
donor
result
eventfre
surviv
rate
overal
surviv
rate
acut
chronic
graftversu
host
diseas
gvhd
adult
sickl
cell
diseas
scd
unmet
need
altern
donor
scd
patient
hlamatch
sibl
hsct
use
hlamatch
unrel
donor
limit
difficulti
find
hlacompat
donor
larg
nonwhit
patient
popul
addit
studi
report
high
rate
chronic
gvhd
transplantrel
mortal
scd
patient
receiv
transplant
hlamatch
unrel
donor
discoveri
posttranspl
cyclophosphamid
ptci
allow
patient
engraft
stem
cell
haploident
donor
without
increas
risk
gvhd
led
rapid
expans
haploident
hsct
patient
hematolog
malign
strategi
use
scd
patient
transplant
bone
marrow
cell
condit
fludarabin
cyclophosphamid
gy
total
bodi
irradi
tbi
antithymocyt
globulin
gvhd
prophylaxi
ptci
day
mycophenol
mofetil
day
tacrolimu
sirolimu
least
year
hopkin
protocol
sever
transplantrel
complic
report
patient
achiev
stabl
donor
cell
engraft
subsequ
studi
regimen
result
engraft
scd
patient
modif
regimen
includ
addit
azathioprin
hydroxyurea
month
prehsct
hypertransfus
thiotepa
day
improv
engraft
acut
gvhd
mortal
pediatr
seri
scd
patient
institut
largest
adult
sickl
cell
program
chicago
area
scd
patient
elig
hsct
match
relat
donor
initi
haploident
hsct
program
report
center
reallif
experi
screen
treat
adult
scd
patient
haploident
hsct
transplant
elig
requir
similar
match
relat
donor
transplant
accord
intern
expert
panel
altern
donor
transplant
scd
addit
requir
recipi
neg
donorspecif
hla
antibodi
dsa
posit
dsa
consid
moder
mean
fluoresc
intens
high
mean
fluoresc
intens
institut
review
board
approv
obtain
collect
analyz
clinic
data
haploident
donor
either
hbaa
hba
donor
receiv
granulocyt
colonystimul
factor
gcsf
subcutan
dose
daili
day
follow
peripher
blood
stem
cell
pbsc
collect
condit
protocol
first
patient
follow
alemtuzumab
mgkg
day
mgkg
day
mgkg
day
singledos
tbi
gy
day
cyclophosphamid
mg
kg
day
patient
fail
engraft
donor
cell
adopt
hopkin
protocol
next
patient
modif
aim
improv
engraft
increas
dose
tbi
gy
gy
infus
growth
factormobil
pbsc
instead
bone
marrow
cell
figur
condit
follow
rabbit
antithymocyt
globulin
sanofi
genzym
cambridg
mgkg
day
mgkg
day
cyclophosphamid
mgkg
day
fludarabin
mgm
day
singledos
tbi
gy
day
gvhd
prophylaxi
consist
cyclophosphamid
mgkg
iv
day
oral
mycophenol
mofetil
mgkg
time
daili
day
sirolimu
day
dose
target
trough
ngml
patient
cell
chimer
year
posthsct
without
sign
gvhd
treatment
sirolimu
taper
month
recipi
underw
rbc
exchang
transfus
day
goal
hb
hydroxyurea
perman
discontinu
day
platelet
transfus
administ
maintain
platelet
count
cellsl
penicillin
v
mg
po
administ
twice
daili
addit
standard
antimicrobi
prophylaxi
donor
cell
engraft
assess
chimer
analysi
circul
mononuclear
cell
cell
day
patient
monitor
univers
illinoi
chicago
bone
barrow
transplant
clinic
least
weekli
day
monthli
day
bimonthli
year
posthsct
acut
chronic
gvhd
grade
accord
standard
consensu
diagnost
criteria
januari
march
adult
scd
patient
meet
haploident
hsct
elig
requir
refer
program
figur
nine
patient
initi
deni
insur
therefor
could
screen
donor
avail
lack
avail
haploident
donor
moder
n
high
n
level
dsa
strong
predictor
graft
reject
haploident
hsct
patient
identifi
haploident
donor
addit
patient
deni
insur
transplant
ultim
declin
defer
hsct
result
total
patient
transplant
recipi
receiv
pbsc
haploident
donor
hba
donor
mobil
gcsf
lead
increas
side
effect
produc
similar
stem
cell
collect
hbaa
donor
first
patient
tabl
top
condit
gy
tbi
ptci
fail
engraft
donor
cell
recov
autolog
neutrophil
day
day
respect
follow
patient
tabl
bottom
condit
modifi
hopkin
regimen
tbi
gy
pbsc
graft
sourc
figur
patient
engraft
neutrophilsl
median
day
rang
one
patient
low
donor
cell
chimer
level
day
spontan
improv
day
without
chang
immunosuppress
anoth
patient
progress
declin
donor
whole
blood
cell
chimer
experienc
secondari
graft
failur
day
autolog
hematopoiet
recoveri
year
posthsct
patient
maintain
averag
donor
mononuclear
chimer
cell
chimer
figur
transplantrel
toxic
includ
least
grade
mucos
patient
cytomegaloviru
reactiv
patient
without
occurr
cytomegaloviru
infect
seven
neutropen
patient
hb
receiv
median
dose
rang
gcsf
start
day
posthsct
patient
experienc
mild
bone
pain
lower
extrem
small
subarachnoid
hemorrhag
occur
patient
first
patient
histori
multipl
rbc
antibodi
becam
refractori
platelet
transfus
develop
multifoc
small
subarachnoid
hemorrhag
left
pariet
lobe
day
symptom
brain
imag
improv
day
later
platelet
count
maintain
cellsl
crossmatch
platelet
second
patient
prior
stroke
histori
develop
seizur
platelet
count
cellsl
magnet
reson
imag
brain
demonstr
right
frontal
subarachnoid
hemorrhag
day
symptom
imag
result
improv
day
later
initi
levetiracetam
maintain
platelet
cellsl
acut
gvhd
observ
patient
chronic
gvhd
patient
one
patient
develop
acut
chronic
gvhd
involv
skin
liver
eye
day
treatment
steroid
strict
complianc
sirolimu
improv
eye
symptom
bilirubin
level
patient
die
unexpectedli
home
day
anoth
patient
develop
grade
ii
acut
gut
gvhd
complet
resolv
short
cours
steroid
therapi
median
followup
month
rang
patient
aliv
maintain
stabl
donor
engraft
figur
improv
hemoglobin
concentr
figur
three
patient
stop
immunosuppress
taper
immunosuppress
singlecent
experi
haploident
hsct
program
adult
scd
demonstr
sever
reallif
barrier
access
haploident
transplant
safeti
gcsf
posthsct
high
rate
longterm
engraft
use
pbsc
modifi
hopkin
regimen
posit
result
match
relat
donor
hsct
initi
attempt
appli
alemtuzumabbas
regimen
addit
ptci
patient
undergo
haploident
hsct
experienc
graft
failur
consist
experi
report
use
approach
nation
institut
health
risk
transplantrel
mortal
higher
adult
scd
use
standard
myeloabl
regimen
transplant
next
patient
nonmyeloabl
regimen
develop
john
hopkin
univers
decreas
high
rate
reject
report
origin
studi
modifi
hopkin
protocol
increas
dose
tbi
gy
gy
use
pbsc
instead
marrow
cell
led
improv
stabl
donor
cell
engraft
previous
report
maintain
manag
toxic
find
report
consid
context
small
seri
haploident
hsct
scd
patient
publish
date
tabl
engraft
result
compar
obtain
pediatr
seri
azathioprin
hydroxyurea
thiotepa
ad
prepar
regimen
use
pbsc
associ
greater
risk
acut
chronic
gvhd
compar
unstimul
bone
marrow
patient
hematolog
malign
undergo
cellreplet
haploident
hsct
although
observ
chronic
gvhd
patient
risk
care
consid
futur
studi
test
benefit
pbsc
reduc
reject
patient
nonmalign
diseas
condit
low
intens
regimen
experi
adult
scd
patient
refer
hsct
end
receiv
haploident
hsct
medic
insur
denial
account
lack
access
hsct
factor
high
rate
dsa
frequent
transfus
scd
patient
person
decis
declin
hsct
also
play
signific
role
rate
avail
haploident
donor
lower
previous
observ
john
hopkin
univers
scd
patient
refer
haploident
donor
differ
may
mani
scd
patient
report
alreadi
follow
clinic
prescreen
select
refer
physician
presenc
dsa
major
barrier
haploident
hsct
scd
address
discuss
treatment
option
patient
possibl
strategi
increas
donor
pool
could
select
patient
low
dsa
titer
neg
crossmatch
result
desensit
protocol
use
hematolog
malign
also
test
clinic
trial
scd
patient
clinic
aggress
diseas
find
consist
previou
report
show
substanti
proport
elig
scd
patient
proceed
hsct
fear
toxic
satisfact
current
qualiti
life
main
reason
patient
report
declin
hsct
risk
gvhd
hlamismatch
hsct
toxic
associ
chemotherapi
condit
regimen
interestingli
previou
studi
sever
scd
associ
degre
risk
parent
patient
will
accept
cure
adolesc
parent
would
accept
hsct
recommend
hematologist
thirtytwo
percent
adolesc
believ
scd
shorten
life
span
believ
scd
prevent
achiev
life
goal
contrast
adult
perceiv
employ
opportun
affect
scd
need
better
educ
patient
cours
scd
larg
prospect
haploident
hsct
studi
guid
decis
patient
famili
risktobenefit
assess
hsct
risk
cur
treatment
altern
donor
need
care
consid
new
therapi
gene
therapi
nontranspl
therapi
develop
scd
also
observ
gcsf
could
safe
administ
scd
adult
shorten
durat
posthsct
neutropenia
concern
safeti
gcsf
highlight
previou
case
seri
scd
patient
receiv
gcsf
reduc
durat
neutropenia
chemotherapi
mobil
autolog
stem
cell
case
seri
patient
seriou
advers
event
gcsf
use
lower
hb
level
reduc
rate
advers
event
contrast
pediatr
cohort
children
scd
undergo
match
relat
donor
hsct
gcsf
safe
given
start
day
full
neutrophil
recoveri
patient
studi
mild
lower
extrem
pain
receiv
gcsf
consist
toler
gcsf
posthsct
scd
although
sickl
cell
trait
donor
experi
sever
side
effect
gcsf
mobil
altern
strategi
mobil
stem
cell
sickl
cell
trait
donor
mobil
autolog
stem
cell
scd
patient
may
use
plerixafor
safe
demonstr
gene
therapi
studi
conclus
find
suggest
nonmyeloabl
haploident
pbsc
transplant
use
tbi
gy
ptci
could
cure
mani
adult
patient
advanc
scd
larger
clinic
studi
warrant
base
find
barrier
limit
access
haploident
hsct
scd
patient
also
address
transplant
commun
multilevel
intervent
pure
rbc
aplasia
prca
uncommon
complic
abo
major
mismatch
allogen
hematopoiet
stem
cell
transplant
hsct
occur
patient
prca
consid
result
b
lymphocyt
recipi
origin
produc
isohemoagglutinin
interfer
engraft
donor
erythroid
cell
character
delay
rbc
recoveri
transplant
anemia
reticulocytopenia
diagnosi
confirm
absenc
erythroblast
otherwis
morpholog
normal
bone
marrow
caus
instanc
viral
infect
drug
toxic
exclud
number
risk
factor
associ
develop
prca
includ
antia
isoagglutinin
use
reducedintens
condit
cyclosporinebas
graftversushost
diseas
gvhd
prophylaxi
absenc
gvhd
graft
match
sibl
donor
although
sever
patient
may
recov
spontan
other
need
aggress
treatment
strategi
avoid
extens
rbc
transfus
relat
iron
overload
rapid
taper
immunosuppress
agent
erythropoietin
recombin
human
erythropoietin
rhuepo
rituximab
bortezomib
plasma
exchang
pex
immunoadsorpt
donor
lymphocyt
infus
mesenchym
stem
cell
antithymocyt
globulin
highdos
steroid
use
treatment
prca
howev
result
report
literatur
therapeut
option
larg
variabl
even
disappoint
mani
case
eltrombopag
oral
thrombopoiet
receptor
agonist
approv
us
food
drug
administr
treatment
patient
immun
thrombocytopen
purpura
sever
aplast
anemia
saa
refractori
immunosuppress
treatment
elig
hsct
hypothes
eltrombopag
might
activ
patient
prca
base
favor
multilineag
respons
observ
patient
saa
particularli
extend
therapi
report
experi
use
eltrombopag
treatment
